




Von Hippel-Lindau Disease Tumor Suppressor (VHL) Antibody

Catalogue No.: abx032864



Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

Target: Von Hippel-Lindau Disease Tumor Suppressor (VHL)

Clonality: Polyclonal

Reactivity: Human, Mouse

Tested Applications: ELISA, WB, IHC, IF/ICC, FCM

Host: Rabbit

Datasheet

Version: 3.0.0

Revision date: 02 May 2025



Recommended dilutions:	WB: 1/2000, IHC-P: 1/25, IF/ICC: 1/25, FCM: 1/25. Not tested in IHC-F. Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Immunogen:	KLH-conjugated synthetic peptide between 43-71 amino acids from the N-terminal region of human VHL.
Isotype:	IgG
Form:	Liquid
Purification:	Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
UniProt Primary AC:	P40337 (UniProt , ExPASy)
NCBI Accession:	NP_000542.1, NP_937799.1
KEGG:	hsa:7428
String:	9606.ENSP00000256474
Molecular Weight:	Calculated MW: 24.2 kDa
Buffer:	PBS containing 0.09% sodium azide.
Specificity:	Predicted to react with Rat VHL.
Note:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.